In order to treat bone defects in diabetes patients, BellaSeno GmbH is working with the Charité on 3D-printed, resorbable implants as part of the SyMBoD consortium.
The SyMBoD consortium is an interdisciplinary project consisting of four universities and an industrial partner and is dedicated to the development of novel, personalized treatments for endogenous bone regeneration in patients with diabetes. The project is funded by the Ministry of Education and Research (BMBF) and managed by the Charité Berlin. Other partners are the University of Freiburg, the Fraunhofer IZI, the Technical University of Munich and Genvention GmbH. SymBoD is part of the BMBF initiative "e:Med", which supports various consortia in systems medicine with a total budget of 200 million euros over a period of eight years.
Within this framework, resorbable implants are to be developed for the personalized treatment of bone defects in patients with diabetes. The company BellaSeno GmbH is a company with expertise in the field of additive manufacturing of resorbable frameworks and is responsible within the project for the ISO 13485-compliant production of medical frameworks. Together with the Charité Universitätsmedizin, the blood supply and the regeneration of stubborn bone defects are to be restored using 3D-printed scaffolds that have been mechanically and biologically optimized.
"3D printed scaffolds that have been mechanically and biologically optimized can improve bone regeneration," says Navid Khani, who heads the research and development department at BellaSeno. “Our custom high-speed additive manufacturing platform is very precise, produces highly reproducible structures and has been certified to the ISO 13485 standard, so we are very well positioned to produce state-of-the-art medical-grade scaffolds for a variety of applications,” says Su Ping Patrina Pohof from the Julius Wolff Institute for Biomechanics and Musculoskeletal Regeneration at the Charité. BellaSeno was chosen as a partner because the team has a high level of expertise in the field of additive manufacturing of porous structures with extremely small features, as required for the planned application. "This strategic inclusion of BellaSeno is also driven by the fact that, to our knowledge, they are the only company in Germany capable of performing the entire additive design and manufacturing process chain with ISO 13485 certified processes." in turn, is an important prerequisite for later application in clinical practice.
The special feature of the BellaSeno process is the very high-resolution lattice-based structure, which can be used to produce 3D-printed resorbable implants reproducibly and with a required unit cell size of less than 3 mm using melt extrusion technology. Using the custom Yasham platform, BellaSenoc can produce reproducible and routine scaffolds with cell sizes down to 1mm through additive manufacturing processes.
The BellaSeno GmbH was founded in 2015 and is located on the BioCity campus in Leipzig. The company has received significant financial support from private investors as well as from the Saxony Development Bank (SAB) and the European Regional Development Fund (ERDF). The company is co-financed from taxes based on the budget passed by the members of the Saxon state parliament. The company recently announced that company founder and CTO Mohit Chhaya has also taken on the role of CEO since the beginning of April. This position was previously held by Simon Champ, who has moved to the Supervisory Board.
Source: Press article medtech zwo from March 29.04.2020rd, XNUMX